Catalyst Funds Management Pty LTD Lineage Cell Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $662 Billion
- Q3 2025
A detailed history of Catalyst Funds Management Pty LTD transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 62,400 shares of LCTX stock, worth $118,560. This represents 0.02% of its overall portfolio holdings.
Number of Shares
62,400Holding current value
$118,560% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
128Shares Held
96MCall Options Held
251KPut Options Held
50K-
Broadwood Capital Inc New York, NY49.6MShares$94.2 Million5.18% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.01MShares$17.1 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.2 Million10.91% of portfolio
-
Comerica Bank4.6MShares$8.74 Million0.03% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $323M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...